Antiangiogenic therapy is a second successful targeted biologic therapy for the treatment of breast cancer. Bevacizumab is now approved in combination with paclitaxel to treat advanced disease, and ongoing trials are investigating bevacizumab alone or in combination in both the early- and late-stage ...
1ST-LINE TREATMENTENDOCRINE THERAPYBreast cancer is a heterogeneous group of diseases that are clinically subdivided as hormone receptor-positive, human epidermal growth factor receptor 2-positive (HER2+), and triple-negative breast cancer, to guide therapeutic interventions. Agents that target estrogen ...
These drugs are used for the treatment of breast cancer for females who are postmenopausal (or who are premenopausal and have received ovarian suppression therapy) to make hormonal therapies more effective.1 Ibrance (palbociclib): This drug inhibits enzymes called cyclin-dependent kinases (CDK4 and ...
Several Trop2-targeted drugs are currently under development, including antibodies, ADCs, and combination therapies, with ADCs at the forefront of cancer therapy and precision medicine. The FDA has approved SG for the treatment of TNBC and HR+/HER2-breast cancer patients. There are several Trop2...
Breast cancer is a complex and heterogeneous disease.Targeted therapies for breast cancer are evolving rapidly.Trastuzumab therapy for HER?2-positive metastatic breast cancer was approved by FDA in 1997.Since that day,other targeted therapies,such as lapatinib,a dual human epidermal growth factor recep...
With a better understanding of the etiology of breast cancer, molecularly targeted drugs have been developed and are being testing for the treatment and prevention of breast cancer. Targeted drugs that inhibit the estrogen receptor (ER) or estrogen-activated pathways include the selective ER modulators...
Traditional therapeutic approaches such as chemotherapy and radiation therapy have burdened cancer patients with onerous physical and psychological challenges. Encouragingly, the landscape of tumor treatment has undergone a comprehensive and remarkable transformation. Emerging as fervently pursued modalities are sm...
The U.S. Food and Drug Administration has approved Enhertu (am-trastuzumab-deruxtecan-nxki), an intravenous infusion treatment for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-low breast cancer.
Several therapeutic modalities, such as surgery, radiation therapy, and systemic anticancer therapy, have been applied clinically for cancer treatment, either alone, in combination, or sequentially, depending on the stage, resectability, biology, comorbidities, and patient’s overall functional performance...
Role of targeted therapy in the treatment of advanced prostate cancer Over the past decade, the treatment of advanced prostate cancer has developed significantly, and perhaps the most dramatic shift came in 2004 with the demo... K Fizazi,CN Sternberg,JM Fitzpatrick,... - 《Bju International》...